Last reviewed · How we verify
Intravenous human immunoglobulin
At a glance
| Generic name | Intravenous human immunoglobulin |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer (PHASE3)
- Monitoring of Donor-specific Antibodies After Treatment With Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation
- Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors (PHASE1)
- A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy (PHASE2)
- Rituximab for Anti-cytokine Autoantibody-Associated Diseases (PHASE1)
- Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery (PHASE2)
- A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV (PHASE1)
- Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous human immunoglobulin CI brief — competitive landscape report
- Intravenous human immunoglobulin updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI